Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Abstracts: AACR Special Conference Molecularly Targeted Therapies: Mechanisms of Resistance-- May 9–12, 2012; San Diego, CA

Poster Presentations

  • Poster Presentations
    Abstract A1: Functional significance of miR-10b in tamoxifen resistance of breast cancer cells
    Aamir Ahmad, Kaladhar B. Reddy and Fazlul H. Sarkar
    Clin Cancer Res May 15 2012 18 (10 Supplement) A1-A1; DOI:10.1158/1078-0432.MECHRES-A1

  • Poster Presentations
    Abstract A2: Selective inhibition of mTORC1/mTORC2 sensitizes prostate cancer cells to the effects of AR or IGF-1R/IR antagonists, providing an approach to overcome intrinsic mechanisms of resistance
    Matthew O'Connor, Elizabeth Buck, Stuart Thomson, David Epstein, Miglarese Mark and Sharon Barr
    Clin Cancer Res May 15 2012 18 (10 Supplement) A2-A2; DOI:10.1158/1078-0432.MECHRES-A2

  • Poster Presentations
    Abstract A3: mTOR signaling and tamoxifen response in postmenopausal breast cancer
    Josefine Bostner, Elin Karlsson, Muneeswaran Jayachandra Pandiyan, Tommy Fornander and Bo Nordenskjöld
    Clin Cancer Res May 15 2012 18 (10 Supplement) A3-A3; DOI:10.1158/1078-0432.MECHRES-A3

  • Poster Presentations
    Abstract A4: A novel class of selective ERα degraders acts as full antagonists/ inverse agonists and displays efficacy in pre-clinical models of endocrine-resistant breast cancer and endometrial cancer
    Beatrice Darimont, Ninh Lu, John Sensintaffar, Kyoung-Jin Lee, Anna Aparicio, Joshua Kaufman, Eric Bischoff, Peter Rix, Rich Heyman, Nicholas Smith, Jeffrey Hager, James Joseph, Katherine Grillot, Jing Qian, Shao Gang, Steven Govek, Johnny Nagasawa, Andiliy Lai and Mehmet Kahraman
    Clin Cancer Res May 15 2012 18 (10 Supplement) A4-A4; DOI:10.1158/1078-0432.MECHRES-A4

  • Poster Presentations
    Abstract A5: Can activation of the UPR lead to Trastuzumab resistance?
    Sreekanth Kumandan, Navin R. Mahadevan, Alexandra DeLaney and Maurizio Zanetti
    Clin Cancer Res May 15 2012 18 (10 Supplement) A5-A5; DOI:10.1158/1078-0432.MECHRES-A5

  • Poster Presentations
    Abstract A6: Sustained MAPK signaling contributes to reduced sensitivity to lapatinib
    Sylvia S. Gayle and Rita Nahta
    Clin Cancer Res May 15 2012 18 (10 Supplement) A6-A6; DOI:10.1158/1078-0432.MECHRES-A6

  • Poster Presentations
    Abstract A7: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer
    Beatrice Darimont, Steven Govek, Nihn Lu, Johnny Nagasawa, Rene Prudente, Jing Qian, John Sensintaffar, Gang Shao, Richard Heyman, Peter Rix, Nicholas Smith, Jeffrey Hager, James Joseph, Katherine Grillot, Anna Aparicio, Eric Bischoff, Mehmet Kahraman, Josh Kaufman, Andiliy Lai and Kyoung-Jin Lee
    Clin Cancer Res May 15 2012 18 (10 Supplement) A7-A7; DOI:10.1158/1078-0432.MECHRES-A7

  • Poster Presentations
    Abstract A8: Combating adaptive ERBB3-mediated resistance to ERBB2 inhibitors: In Silico optimization of MM-111 and lapatinib dosing regimens
    Daniel C. Kirouac, Johanna Lahdenranta, Ryan Overland, Jinyan Du, Charlotte McDonagh, Ulrik Nielson and Mathew Onsum
    Clin Cancer Res May 15 2012 18 (10 Supplement) A8-A8; DOI:10.1158/1078-0432.MECHRES-A8

  • Poster Presentations
    Abstract A9: The cocaine and amphetamine-regulated transcript (CART) is an independent prognostic factor in lymph node-negative breast cancer and predicts outcome in tamoxifen treated patients
    Darran O'Connor, Donal Brennan, Henriette Laursen, Rene Bernards, John Crown, Karin Jirstrom and William Gallagher
    Clin Cancer Res May 15 2012 18 (10 Supplement) A9-A9; DOI:10.1158/1078-0432.MECHRES-A9

  • Poster Presentations
    Abstract A10: Peroxiredoxin-1 and oxidative stress: Controlling the balance between oncogenic and endocrine signalling in estrogen receptor-positive breast cancer
    Patrick C. O'Leary, Donal J. Brennan, John Crown, William M. Gallagher, Radoslaw Zagozdzon, Yue Fan, Bryan T. Hennessy, Ana-Maria Gonzalez-Angulo, Gordon Mills, Fredrik Ponten, Karin Jirstrom, Mathias Uhlen and Darran O'Connor
    Clin Cancer Res May 15 2012 18 (10 Supplement) A10-A10; DOI:10.1158/1078-0432.MECHRES-A10

  • Poster Presentations
    Abstract A12: Identification of Nrdp1 as a novel androgen receptor transcription target differentially regulated in androgen-dependent and independent prostate cancer
    Rosalinda M. Savoy, Liqun Chen, Dean Troyer, Paramita Ghosh, William Fry, Kermit Carraway, Slama Siddiqui, Frank Melgoza, Mohana Roy, Ryan E. Beggs, Maitreyee K. Jathal, Swagata Bose, Yu Wang and Roble Bedolla
    Clin Cancer Res May 15 2012 18 (10 Supplement) A12-A12; DOI:10.1158/1078-0432.MECHRES-A12

  • Poster Presentations
    Abstract A14: Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
    Aoife Ward, Aleksandra Balwierz, Jitao David Zhang, Moritz Kueblbeck, Stefan Wiemann, Thomas Hielscher, Yudi Pawitan and Ozgur Sahin
    Clin Cancer Res May 15 2012 18 (10 Supplement) A14-A14; DOI:10.1158/1078-0432.MECHRES-A14

  • Poster Presentations
    Abstract A16: Molecular mechanisms of EGFR therapy resistance in breast cancer cells
    Linette Castillo-Pichardo, Luis D. Borrero-Garcia, Roxana S. Redis, George A. Calin, Luis A. Cubano and Suranganie Dharmawardhane
    Clin Cancer Res May 15 2012 18 (10 Supplement) A16-A16; DOI:10.1158/1078-0432.MECHRES-A16

  • Poster Presentations
    Abstract A17: Loss of DEPTOR increases resistance to EGFR tyrosine kinase inhibitors by upregulating EGFR and MAPK signaling
    Catherine F. Cowell, Elza C. De Bruin, Michael Howell and Julian Downward
    Clin Cancer Res May 15 2012 18 (10 Supplement) A17-A17; DOI:10.1158/1078-0432.MECHRES-A17

  • Poster Presentations
    Abstract A18: Reduced NF1 expression in resistance to EGF receptor inhibitory drugs in lung adenocarcinoma
    Elza de Bruin, Catherine Cowell, Michael Howell, Harold Varmus, Katerina Politi and Julian Downward
    Clin Cancer Res May 15 2012 18 (10 Supplement) A18-A18; DOI:10.1158/1078-0432.MECHRES-A18

  • Poster Presentations
    Abstract A19: A qPCR assay, OncoScore Colon, predicts resistance to cetuximab in formalin-fixed, paraffin-embedded colorectal cancer tissue independent of KRAS status
    Sean Eddy, Byung-In Lee, Teresa Macarulla, Josep Tabernero, Joseph Monforte, Daniel R. Rhodes, Paul Williams, Mark Tomilo, Seth Sadis, Peter Wyngaard, Lien Vo, Kahuku Oades, Hyunsoo Kim and Yipeng Wang
    Clin Cancer Res May 15 2012 18 (10 Supplement) A19-A19; DOI:10.1158/1078-0432.MECHRES-A19

  • Poster Presentations
    Abstract A20: DARPP-32-mediated EGFR protein stability leads to gefitinib resistance in gastric cancer
    Shoumin Zhu, Abbes Belkhiri and Wael El-Rifai
    Clin Cancer Res May 15 2012 18 (10 Supplement) A20-A20; DOI:10.1158/1078-0432.MECHRES-A20

  • Poster Presentations
    Abstract A21: Dual-kinase inhibition of EGFR/ERBB2 as a therapeutic strategy in prostate cancer
    Maitreyee K. Jathal, Benjamin A. Mooso, Leandro S. D'Abronzo and Paramita M. Ghosh
    Clin Cancer Res May 15 2012 18 (10 Supplement) A21-A21; DOI:10.1158/1078-0432.MECHRES-A21

  • Poster Presentations
    Abstract A22: Effectiveness of ErbB inhibitors in the treatment of bladder cancer
    Benjamin A. Mooso and Paramita M. Ghosh
    Clin Cancer Res May 15 2012 18 (10 Supplement) A22-A22; DOI:10.1158/1078-0432.MECHRES-A22

  • Poster Presentations
    Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer
    Ken Takezawa, Mary Ann Melnick, Greg Riely, Mark Kris, Vincent Miller, Marc Ladanyi, Katerina Politi, William Pao, Valentina Pirazzoli, Xiaoling Song, Maria Arcila, Elisa De Stanchina, Kadoaki Ohashi, Yelena Janjigian, Paula Spitzler and Caroline Nebhan
    Clin Cancer Res May 15 2012 18 (10 Supplement) A23-A23; DOI:10.1158/1078-0432.MECHRES-A23

  • Poster Presentations
    Abstract A24: Fibronectin-mediated activation of Stat3 facilitates the resistance of triple negative breast cancer to EGFR-targeted therapies
    Michael K. Wendt, Nikolas Balanis, Cathleen Carlin and William Schiemann
    Clin Cancer Res May 15 2012 18 (10 Supplement) A24-A24; DOI:10.1158/1078-0432.MECHRES-A24

  • Poster Presentations
    Abstract A25: Uncommon mutation types of Epidermal Growth Factor Receptor (EGFR) and tyrosine kinase inhibitor response in non-small cell lung carcinoma
    Maria P. Wong, Victor H.F. Lee, Rebecca M.W. Yeung, Vicky P.C. Tin, Kit Chi Choy and Jing Liu
    Clin Cancer Res May 15 2012 18 (10 Supplement) A25-A25; DOI:10.1158/1078-0432.MECHRES-A25

  • Poster Presentations
    Abstract A27: PI3K/Akt pathway-dependent and -independent mechanisms of resistance to EGFR tyrosine kinase inhibitors in glioblastoma
    Jill Wykosky, Webster Cavenee and Frank Furnari
    Clin Cancer Res May 15 2012 18 (10 Supplement) A27-A27; DOI:10.1158/1078-0432.MECHRES-A27

  • Poster Presentations
    Abstract A29: Different PIK3CA activation mutations can lead to distinct signaling mechanisms and EGFR inhibitor sensitivities in colorectal cancer cells
    Matthew J. Wong, Marie-Claire Wagle, Garret Hampton and Yibing Yan
    Clin Cancer Res May 15 2012 18 (10 Supplement) A29-A29; DOI:10.1158/1078-0432.MECHRES-A29

  • Poster Presentations
    Abstract A31: Roles of Nogo-B receptor (NgBR) in regulating Ras translocation and modulating breast cancer cell sensitivity to chemotherapeutic drug and irradiation
    Baofeng Zhao, Zhong Liu, Suresh Kumar and Robert Q. Miao
    Clin Cancer Res May 15 2012 18 (10 Supplement) A31-A31; DOI:10.1158/1078-0432.MECHRES-A31

  • Poster Presentations
    Abstract A32: Notch signaling regulates recurrence in a model of HER2 targeted therapy
    Daniel L. Abravanel, Christopher J. Sterner, Tien-chi Pan, George K. Belka and Lewis A. Chodosh
    Clin Cancer Res May 15 2012 18 (10 Supplement) A32-A32; DOI:10.1158/1078-0432.MECHRES-A32

  • Poster Presentations
    Abstract A33: Modeling clinical resistance to RAF inhibitors in an in vivo melanoma model provides insights into prevention of resistance
    Meghna Das Thakur, Fernando Salangsang, Nancy Pryer, Martin McMahon and Darrin Stuart
    Clin Cancer Res May 15 2012 18 (10 Supplement) A33-A33; DOI:10.1158/1078-0432.MECHRES-A33

  • Poster Presentations
    Abstract A36: Doxorubicin loaded lactoferrin nanoparticles: Treatment of hepatocellular carcinoma in rats induced by diethylnitrosamine
    Kishore Golla, Bhaskar Cherukuvada, Ahmed Farhan and Anand Kumar Kondapi
    Clin Cancer Res May 15 2012 18 (10 Supplement) A36-A36; DOI:10.1158/1078-0432.MECHRES-A36

  • Poster Presentations
    Abstract A37: Anti-telomerase therapy provokes ALT and mitochondrial adaptive mechanism in cancer
    Jian Hu, Sarah Hwang, Adam Boutin, Alan Wang, Lynda Chin, Marc Liesa, Orian Shiriha and Ronald DePinho
    Clin Cancer Res May 15 2012 18 (10 Supplement) A37-A37; DOI:10.1158/1078-0432.MECHRES-A37

  • Poster Presentations
    Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas
    Valentina Pirazzoli, Ken Takezawa, Elisa de Stanchina, William Pao and Katerina Politi
    Clin Cancer Res May 15 2012 18 (10 Supplement) A38-A38; DOI:10.1158/1078-0432.MECHRES-A38

  • Poster Presentations
    Abstract A39: The exploration of novel strategy for treatment of pancreactic ductal adenocarcinoma targeting tumor microenvironment with multi-kinase inhibitors
    Motohisa Tada, Fumio Imazeki, Masao Omata, Harold L. Moses, Osamu Yokosuka, Hideaki Ijichi, Fumihiko Kanai, Yoshinari Asaoka, Dai Mohri, Koji Miyabayashi, Tsuneo Ikenoue, Rintarou Mikata and Katsunobu Tawada
    Clin Cancer Res May 15 2012 18 (10 Supplement) A39-A39; DOI:10.1158/1078-0432.MECHRES-A39

  • Poster Presentations
    Abstract A41: Developing a mouse model of melanoma to identify drug resistance mechanisms
    James P. Robinson, Sheri L. Holmen and Matthew VanBrocklin
    Clin Cancer Res May 15 2012 18 (10 Supplement) A41-A41; DOI:10.1158/1078-0432.MECHRES-A41

  • Poster Presentations
    Abstract A42: Sensitivity and resistance to a p-AKT inhibitor in an erlotinib-sensitive model for lung cancer
    Rajaa El Meskini, Philip L. Martin, Michelle Gumprecht, Alan Kulaga, Theresa Guerin, Maureen Baran, Anthony J. Iacovelli, Terry Van Dyke and Zoe Weaver
    Clin Cancer Res May 15 2012 18 (10 Supplement) A42-A42; DOI:10.1158/1078-0432.MECHRES-A42

  • Poster Presentations
    Abstract A43: The Pi3K inhibitor GSK2126458 is highly toxic in breast ductal carcinoma
    Alia Albawardi, Saeeda Almarzooqi, Mohamed Al Bashir and Abdul-Kader Souid
    Clin Cancer Res May 15 2012 18 (10 Supplement) A43-A43; DOI:10.1158/1078-0432.MECHRES-A43

  • Poster Presentations
    Abstract A44: The Pi3K inhibitor GSK2126458 is highly toxic in ovarian dysgerminoma
    Saeeda Almarzooqi, Alia Albawardi and Abdul-Kader Souid
    Clin Cancer Res May 15 2012 18 (10 Supplement) A44-A44; DOI:10.1158/1078-0432.MECHRES-A44

  • Poster Presentations
    Abstract A45: Signaling Events Associated with Cytoprotective Induction of Nitric Oxide Synthase in a Photodynamic Therapy Model
    Reshma Bhowmick and Albert W. Girotti
    Clin Cancer Res May 15 2012 18 (10 Supplement) A45-A45; DOI:10.1158/1078-0432.MECHRES-A45

  • Poster Presentations
    Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer
    Erica L. Bradshaw-Pierce, Todd M. Pitts, Kelly L. McPhillips, Daniel L. Gustafson, Aik-Choon Tan, Leslie Nguyen, Mark West, Timothy Fisher, Brion W. Murray and S. Gail Eckhardt
    Clin Cancer Res May 15 2012 18 (10 Supplement) A46-A46; DOI:10.1158/1078-0432.MECHRES-A46

  • Poster Presentations
    Abstract A47: Inhibition of Rho kinase signaling in angiosarcomas leads to decreased tumor growth and invasiveness, but enhanced resistance to standard chemotherapeutics
    Dianne Courtenay Mitchell and Brad Allen Bryan
    Clin Cancer Res May 15 2012 18 (10 Supplement) A47-A47; DOI:10.1158/1078-0432.MECHRES-A47

  • Poster Presentations
    Abstract A49: Combination of bendamustine and the HDAC inhibitor entinostat enhances apoptosis and DNA damage response in multiple myeloma cells
    Bo Cai, Jingcao Huang, Choon-Kee Lee and Bolin Liu
    Clin Cancer Res May 15 2012 18 (10 Supplement) A49-A49; DOI:10.1158/1078-0432.MECHRES-A49

  • Poster Presentations
    Abstract A50: Development of a quantitative RON SRM Assay for use in formalin fixed tumor tissues
    Todd Hembrough, Wei-Li Liao, Les Henderson, Peng Xu, Jon Burrows and Daniel Catenacci
    Clin Cancer Res May 15 2012 18 (10 Supplement) A50-A50; DOI:10.1158/1078-0432.MECHRES-A50

  • Poster Presentations
    Abstract A51: Antiproliferative activity of F14512, a novel polyamine-vectorized drug, on multidrug resistant cancer cells
    Laurent Créancier, Nicolas Guilbaud, Jean-Philippe Annereau, Viviane Brel, Marie-Laure Marionneau-Brossard, Vanessa Offrete, Jérôme Verdier, Karine André, Emmanuel Fournier, Yves Guminski and Anna Kruczynski
    Clin Cancer Res May 15 2012 18 (10 Supplement) A51-A51; DOI:10.1158/1078-0432.MECHRES-A51

  • Poster Presentations
    Abstract A52: Comparison of the efficacy of different mTOR inhibitors for the treatment of prostate cancer
    Leandro Salati D'Abronzo, Ryan Beggs, Swagata Bose and Paramita Ghosh
    Clin Cancer Res May 15 2012 18 (10 Supplement) A52-A52; DOI:10.1158/1078-0432.MECHRES-A52

  • Poster Presentations
    Abstract A53: Bayesian Network Inference Modeling Reveals Novel Regulators of Cell Cycle Progression and Survival
    Rina Gendelman, Heming Xing, Preeti Sarde, Olga K. Mirzoeva, Heidi Feiler, Joe W. Gray, Paul McDonagh, Iya Khalil and W. Michael Korn
    Clin Cancer Res May 15 2012 18 (10 Supplement) A53-A53; DOI:10.1158/1078-0432.MECHRES-A53

  • Poster Presentations
    Abstract A54: Potential mechanisms of resistance to targeted agents in human clear cell renal cell carcinoma
    Adrian G. Grozav, Susan A.J. Vaziri, Koegle R. Eric, Dale R. Grabowski, Ronald M. Bukowski, Mahrukh K. Ganapathi and Ram N. Ganapathi
    Clin Cancer Res May 15 2012 18 (10 Supplement) A54-A54; DOI:10.1158/1078-0432.MECHRES-A54

  • Poster Presentations
    Abstract A56: Canine Mast Cell Tumor and Toceranib Phosphate (Palladia™): Development of a Spontaneous Canine Model of Kinase Inhibitor Resistance
    Charles H.C. Halsey, Barbara J. Rose, Daniel L. Gustafson and Douglas H. Thamm
    Clin Cancer Res May 15 2012 18 (10 Supplement) A56-A56; DOI:10.1158/1078-0432.MECHRES-A56

  • Poster Presentations
    Abstract A57: Chondroitin sulfate proteoglycan 4(CSPG4) Mediates Melanoma Cell Survival During PI3K and mTOR Inhibition
    Sehrish Javaid, Leah E. Colvin Wanshura and Arkadiusz Z. Dudek
    Clin Cancer Res May 15 2012 18 (10 Supplement) A57-A57; DOI:10.1158/1078-0432.MECHRES-A57

  • Poster Presentations
    Abstract A60: Targeting p38 MAPK Signaling Pathway in Docetaxel Resistant Prostate Cancer
    Weijuan Li
    Clin Cancer Res May 15 2012 18 (10 Supplement) A60-A60; DOI:10.1158/1078-0432.MECHRES-A60

  • Poster Presentations
    Abstract A61: Profile of Ponatinib, BGJ398, AZ4547 and DCC-2036 against FGFR2 Mutations identified in a Dovitinib Resistance BaF3 Screen
    David Loch, Sara Byron, Andreas Wortman, Huaibin Chen, Moosa Mohammadi and Pamela Pollock
    Clin Cancer Res May 15 2012 18 (10 Supplement) A61-A61; DOI:10.1158/1078-0432.MECHRES-A61

  • Poster Presentations
    Abstract A62: The Bcl-2 associated athanogene 5 binds the molecular chaperone GRP78/BiP and increases chemoresistance in prostate cancer cells
    Anja Bruchmann, Corinna Roller, Tamara Vanessa Walther, Andrew Cato and Danilo Maddalo
    Clin Cancer Res May 15 2012 18 (10 Supplement) A62-A62; DOI:10.1158/1078-0432.MECHRES-A62

  • Poster Presentations
    Abstract A64: NFκB-IκBα Interaction: A Mechanism of Resistance to Cisplatin in Non Small Cell Lung Cancer (NSCLC)
    Susan Heavey, Martin Barr, Peter Godwin, Connla Edwards, Ken O'Byrne and Kathy Gately
    Clin Cancer Res May 15 2012 18 (10 Supplement) A64-A64; DOI:10.1158/1078-0432.MECHRES-A64

  • Poster Presentations
    Abstract A65: Combinational siRNA silencing of MCL-1 and P-gp enhances the apoptotic response in Human Breast Cancer Cells
    Hamidreza Montazeri Aliabadi and Hasan Uludag
    Clin Cancer Res May 15 2012 18 (10 Supplement) A65-A65; DOI:10.1158/1078-0432.MECHRES-A65

  • Poster Presentations
    Abstract A66: Galectin-1 expression correlated with mesenchymal differentiation and resistance to chemotherapy in carcinoma cells
    Lucile Astorgues-Xerri, Eric Raymond, Sandrine Faivre, Caroline Halimi, Annemilai Tijeras-Raballand, Maria Eugenia Riveiro, Sebastien Albert, Maria Serova, Anne Couvelard, Muriel Hourseau and Armand de Gramont
    Clin Cancer Res May 15 2012 18 (10 Supplement) A66-A66; DOI:10.1158/1078-0432.MECHRES-A66

  • Poster Presentations
    Abstract A68: Tumor cell dedifferentiation into endothelial cells and resistance to sunitinib in renal carcinoma models
    Maria Serova, Annemilai Tijeras-Raballand, Celia Dos Santos, Maria Eugenia Riveiro, Armand de Gramont, Sandrine Faivre and Eric Raymond
    Clin Cancer Res May 15 2012 18 (10 Supplement) A68-A68; DOI:10.1158/1078-0432.MECHRES-A68

  • Poster Presentations
    Abstract B1: Dual mTORC1/mTORC2 inhibition limits tumor growth, VEGF production and vascular regrowth
    Sharon Barr, Beverly L. Falcon, Prafulla C. Ghokale, Jeyling Chou, Jennifer Fogarty, Philippe Depeille, Mark Miglarese and David M. Epstein
    Clin Cancer Res May 15 2012 18 (10 Supplement) B1-B1; DOI:10.1158/1078-0432.MECHRES-B1

  • Poster Presentations
    Abstract B2: Supplementation of dietary fish oil induces apoptosis through activation of PPARγ and involves inhibition of angiogenesis in colon cancer
    Shevali Kansal, Anjana K. Negi and Navneet Agnihotri
    Clin Cancer Res May 15 2012 18 (10 Supplement) B2-B2; DOI:10.1158/1078-0432.MECHRES-B2

  • Poster Presentations
    Abstract B3: Angiotensin IV-Related Hepatocyte Growth Factor Antagonists act as Anti-Angiogenic Anti-Cancer Agents
    Leen H. Kawas, Brandi C. Ward, Chromewell Mojica, John W. Wright and Joseph W. Harding
    Clin Cancer Res May 15 2012 18 (10 Supplement) B3-B3; DOI:10.1158/1078-0432.MECHRES-B3

  • Poster Presentations
    Abstract B4: Everolimus inhibits invasion and angiogenesis in a KRAS-mutated mesenchymal-differentiated colorectal cancer xenografts
    Annemilai Tijeras-Raballand, Celia Dos Santos, Maria Serova, Maria Eugenia Riveiro, Armand de Gramont, Sandrine Faivre and Eric Raymond
    Clin Cancer Res May 15 2012 18 (10 Supplement) B4-B4; DOI:10.1158/1078-0432.MECHRES-B4

  • Poster Presentations
    Abstract B5: CpG-siRNA conjugates: Overcoming cancer immunoresistance
    Sergey Nechaev, Qifang Zhang, Piotr Swiderski and Marcin Kortylewski
    Clin Cancer Res May 15 2012 18 (10 Supplement) B5-B5; DOI:10.1158/1078-0432.MECHRES-B5

  • Poster Presentations
    Abstract B6: PEGPH20 depletion of pericellular hyaluronan sensitizes high hyaluronan-producing tumor cells in antibody-dependent cell-mediated cytotoxicity
    Netai C. Singha, Ping Jiang, Susan Zimmerman, Robert Connor, Gregory I. Frost, Zhongdong Huang and H. Michael Shepard
    Clin Cancer Res May 15 2012 18 (10 Supplement) B6-B6; DOI:10.1158/1078-0432.MECHRES-B6

  • Poster Presentations
    Abstract B7: Annexin V inhibits local but not systemic murine fibrosarcoma growth by blocking phosphatidylserine
    Maen Masadeh, Chaobo Yin and Joel Shilyansky
    Clin Cancer Res May 15 2012 18 (10 Supplement) B7-B7; DOI:10.1158/1078-0432.MECHRES-B7

  • Poster Presentations
    Abstract B8: FOXD3 enhances expression of ERBB3 and promotes resistance to vemurafenib
    Kevin J. Basile, Ethan V. Abel and Andrew E. Aplin
    Clin Cancer Res May 15 2012 18 (10 Supplement) B8-B8; DOI:10.1158/1078-0432.MECHRES-B8

  • Poster Presentations
    Abstract B9: Activated MAPK Pathway Mediates Resistance to Romidepsin via Bim Degradation in Romidepsin-Selected HuT 78 Cells
    Arup Chakraborty, Robert Robey, Jean-Pierre Gillet, Victoria Luchenko, Richard Piekarz, Michael Gottesman, Nathan Collie and Susan Bates
    Clin Cancer Res May 15 2012 18 (10 Supplement) B9-B9; DOI:10.1158/1078-0432.MECHRES-B9

  • Poster Presentations
    Abstract B10: Overcoming resistance to B-Raf targeting agents using LPD nanotechnology
    Chin-Ying Chung, Yuhua Wang, Wei-Yun Sheng, Yu-Cheng Tseng, Taryn Dick, Leaf Huang and Gavin Robertson
    Clin Cancer Res May 15 2012 18 (10 Supplement) B10-B10; DOI:10.1158/1078-0432.MECHRES-B10

  • Poster Presentations
    Abstract B12: PTEN modulates sensitivity to a novel ERK inhibitor in BRAFV600E-mutant melanomas
    Clemens Krepler, Meenhard Herlyn, Jessie Villanueva, Ahmed Samatar, Yuhao Chen, Molly Halloran, Minu Samanta, Xu He, Adina Vultur, Bradley Wubbenhorst and Katherine Nathanson
    Clin Cancer Res May 15 2012 18 (10 Supplement) B12-B12; DOI:10.1158/1078-0432.MECHRES-B12

  • Poster Presentations
    Abstract B13: Modeling BRAF inhibitor resistance in genetically engineered mouse models of melanoma
    Lawrence N. Kwong, Shan Jiang and Lynda Chin
    Clin Cancer Res May 15 2012 18 (10 Supplement) B13-B13; DOI:10.1158/1078-0432.MECHRES-B13

  • Poster Presentations
    Abstract B14: Inherent resistance to BRAF inhibitors in BRAFV600E colorectal tumors is driven by ligand-dependent activation of the EGFR pathway
    Ivana Yen, Bonnie Liu, Hartmut Koeppen, Georgia Hatzivassiliou, Shiva Malek, Kyung Song, Patricia Pacheco, Leanne Berry Ross, Stephen Gould, Stephen Schmidt, Joachim Rudolph, Lori Friedman and Marcia Belvin
    Clin Cancer Res May 15 2012 18 (10 Supplement) B14-B14; DOI:10.1158/1078-0432.MECHRES-B14

  • Poster Presentations
    Abstract B15: The pan-BCR-ABL inhibitor ponatinib inhibits viability of gatekeeper mutant BCR-ABLT315I cells with greater potency than a nilotinib/MEK inhibitor combination
    Alexa B. Schrock, Joseph M. Gozgit and Victor Rivera
    Clin Cancer Res May 15 2012 18 (10 Supplement) B15-B15; DOI:10.1158/1078-0432.MECHRES-B15

  • Poster Presentations
    Abstract B17: Mechanisms of resistance of BRAF fusions to first generation selective BRAF inhibitors
    Angela Jae Sievert, Shih-Shan Lang, Phillip B. Storm and Adam C. Resnick
    Clin Cancer Res May 15 2012 18 (10 Supplement) B17-B17; DOI:10.1158/1078-0432.MECHRES-B17

  • Poster Presentations
    Abstract B19: The HSP90 inhibitor, AT13387, is effective against multiple mechanisms of kinase inhibitor resistance
    Ana Rodriguez-Lopez, Tomoko Smyth, Rachel McMenamin, John Lyons, Neil Thompson, Victoria Lock, Pietro Taverna, Robert Corringham and Nicola Wallis
    Clin Cancer Res May 15 2012 18 (10 Supplement) B19-B19; DOI:10.1158/1078-0432.MECHRES-B19

  • Poster Presentations
    Abstract B20: A genome-scale RNA interference screen for resistance mechanisms to BRAF inhibition in melanoma
    Steven Whittaker, Eran Hodis, Nikhil Wagle, Jessica Hsiao, Glenn Cowley, David Root and Levi Garraway
    Clin Cancer Res May 15 2012 18 (10 Supplement) B20-B20; DOI:10.1158/1078-0432.MECHRES-B20

  • Poster Presentations
    Abstract B21: Resistance to B-RAF inhibitor is mediated by reactivation of MAPK pathway by FGFR3/Ras signaling in B-RAF V600E mutant melanoma
    Vipin Yadav, Xiaoyi Zhang, Jiangang Liu, Shawn Estrem, Shuyu Dan Li, Xue-Qian Gong, Sean Buchanan, James R. Henry, James J. Starling and Sheng-Bin Peng
    Clin Cancer Res May 15 2012 18 (10 Supplement) B21-B21; DOI:10.1158/1078-0432.MECHRES-B21

  • Poster Presentations
    Abstract B22: Re-expression of miR-200 by natural agents regulates the expression of PTEN and MT1-MMP in pancreatic cancer
    Shadan Ali, Omar Soubani, Azfur Ali, Farah Logna, Philip Philip and Fazlul Sarkar
    Clin Cancer Res May 15 2012 18 (10 Supplement) B22-B22; DOI:10.1158/1078-0432.MECHRES-B22

  • Poster Presentations
    Abstract B23: Reprogramming of the cancer kinome in response to targeted kinase inhibition
    James S. Duncan, Marty W. Whittle, Lee M. Graves and Gary L. Johnson
    Clin Cancer Res May 15 2012 18 (10 Supplement) B23-B23; DOI:10.1158/1078-0432.MECHRES-B23

  • Poster Presentations
    Abstract B24: De novo and acquired resistance to first-line standard therapy in colorectal cancer: from cell lines to metastatic tumors
    Raquel Aloyz, Caroline Rousseau, Zuanel Diaz, Adriana Aguilar-Mahecha, Mark Basik, Luc Bélanger, Marguerite Buchanan, Errol Camlioglu, Andre Constantin, Naciba Benlimame, Suzan McNamara, Zuanel Diaz, Michèle Orain, Ewa Przybytkowski, Alan Spatz, Bernard Têtu, Lawrence Panasci, Gerald Batist, Michel Lebel, Jean-Yves Masson, David Davidson, Eric R. Paquet, Haji Hassan Houssein, Annie Maltais and Therese Gagnon-Kugler
    Clin Cancer Res May 15 2012 18 (10 Supplement) B24-B24; DOI:10.1158/1078-0432.MECHRES-B24

  • Poster Presentations
    Abstract B25: The Effects of PI3K/Akt/mTOR Pathway Inhibitors on a Panel of Non Small Cell Lung Cancer (NSCLC) Cell Lines
    Susan Heavey, Martin Barr, Anthony Davies, Ken O'Byrne and Kathy Gately
    Clin Cancer Res May 15 2012 18 (10 Supplement) B25-B25; DOI:10.1158/1078-0432.MECHRES-B25

  • Poster Presentations
    Abstract B26: Drug-Diagnostic co-development to target FLT3-ITD mutations in chemo-resistant acute myeloid leukemia cells
    Ching-Huai Ko, Chen Ting-Shou, Lin Mei-Wei, Lai Chin-Pen, Kuo Wen-Hsun, Hwang Chrong-Shiong, Wang Ling-Mei and Tsai Jane SC
    Clin Cancer Res May 15 2012 18 (10 Supplement) B26-B26; DOI:10.1158/1078-0432.MECHRES-B26

  • Poster Presentations
    Abstract B28: Downregulation of vimentin confers resistance to the microtubule stabilizing agents peloruside A and laulimalide in 1A9 human ovarian carcinoma cells
    Arun Kanakkanthara, Pisana Rawson, Peter T. Northcote and John H. Miller
    Clin Cancer Res May 15 2012 18 (10 Supplement) B28-B28; DOI:10.1158/1078-0432.MECHRES-B28

  • Poster Presentations
    Abstract B29: TGF-β2 induction in head and neck squamous cell carcinoma cell lines upon treatment with tyrosine kinase inhibitors as a mechanism of acquired resistance
    Emily K. Kleczko, Lydia Heasley and Lynn E. Heasley
    Clin Cancer Res May 15 2012 18 (10 Supplement) B29-B29; DOI:10.1158/1078-0432.MECHRES-B29

  • Poster Presentations
    Abstract B30: Colorectal cancer HCT116 cells resistant toward a novel Aurora kinase inhibitor CYC116: Molecular hallmarks of drug resistance and pharmacologic interventions restoring the drug sensitivity
    Madhusudhan Reddy Kollareddy, Daniella Zheleva, Josef Srovnal, Lenka Radova, Petr Dzubak, Pathik Subhashchandra Brahmkshatriya and Marian Hajduch
    Clin Cancer Res May 15 2012 18 (10 Supplement) B30-B30; DOI:10.1158/1078-0432.MECHRES-B30

  • Poster Presentations
    Abstract B31: HuR cytoplasmic translocation and doxorubicin: how phosphorylation is involved in chemoresistance
    Elisa Latorre, Alessandro Quattrone and Alessandro Provenzani
    Clin Cancer Res May 15 2012 18 (10 Supplement) B31-B31; DOI:10.1158/1078-0432.MECHRES-B31

  • Poster Presentations
    Abstract B32: Impact of Lipid-Substitution on Assembly and Delivery of siRNA by Cationic Polymers
    Hamidreza Montazeri Aliabadi and Hasan Uludag
    Clin Cancer Res May 15 2012 18 (10 Supplement) B32-B32; DOI:10.1158/1078-0432.MECHRES-B32

  • Poster Presentations
    Abstract B33: PTTG1 expression predicts sensitivity to the Src inhibitor Saracatinib in ovarian cancer cell lines
    Ichiro Nakachi, Barbara A. Helfrich, Christopher D. Coldren, Robert S. Stearman, Jessica L. Rice, Amber R. Cornelius and Monique A. Spillman
    Clin Cancer Res May 15 2012 18 (10 Supplement) B33-B33; DOI:10.1158/1078-0432.MECHRES-B33

  • Poster Presentations
    Abstract B34: Bortezomib induces G2-M arrest through ROS-inducible phosphorylation of ATM-CHK1 in human colon cancer cells
    Hong Seung-Woo, Kim Tae Won, Moon Jai-Hee, Hong Yong-Sang, Jin Dong-Hoon, Shin Jae-Sik, Yoon Dok Hyun, Kim Kyu-pyo, Lee Jae-Lyun and Lee Jung Shin
    Clin Cancer Res May 15 2012 18 (10 Supplement) B34-B34; DOI:10.1158/1078-0432.MECHRES-B34

  • Poster Presentations
    Abstract B35: Alternate receptor tyrosine kinases provide protection from FGFR inhibition in HNSCC cells as identified by genome-wide shRNA screening
    Katherine R. Singleton, Aik-Choon Tan, Jihye Kim and Lynn Heasley
    Clin Cancer Res May 15 2012 18 (10 Supplement) B35-B35; DOI:10.1158/1078-0432.MECHRES-B35

  • Poster Presentations
    Abstract B36: Re-activation of protein phosphatase 2A as a multi-target strategy for combating chemotherapy resistance of common cancer types
    Amanpreet Kaur, Anna Cvrljevic and Jukka Westermarck
    Clin Cancer Res May 15 2012 18 (10 Supplement) B36-B36; DOI:10.1158/1078-0432.MECHRES-B36

  • Poster Presentations
    Abstract B37: Monitoring kinome response to EGFR inhibition in triple negative breast cancer
    Martin C. Whittle, James S. Duncan, Lee M. Graves and Gary L. Johnson
    Clin Cancer Res May 15 2012 18 (10 Supplement) B37-B37; DOI:10.1158/1078-0432.MECHRES-B37

  • Poster Presentations
    Abstract B39: Mechanisms of multidrug resistance in AMLs and selective targeting via small molecules
    Chengguo Xing, David Hermanson and Sonia Das
    Clin Cancer Res May 15 2012 18 (10 Supplement) B39-B39; DOI:10.1158/1078-0432.MECHRES-B39

  • Poster Presentations
    Abstract B40: Paracrine interactions through CXCL1/2 chemokines promote breast cancer metastasis and chemoresistance
    Swarnali Acharyya, Thordur Oskarsson, Sakari Vanharanta, Srinivas Malladi, Juliet Kim, Edi Brogi, Larry Norton and Joan Massague
    Clin Cancer Res May 15 2012 18 (10 Supplement) B40-B40; DOI:10.1158/1078-0432.MECHRES-B40

  • Poster Presentations
    Abstract B41: Thymoquinone induces-cell cycle non-specific-cell death in cisplatin-resistant ovarian cancer cell through up-regulation of PTEN expression
    El-Shaimaa A. Arafa and Altaf A. Wani
    Clin Cancer Res May 15 2012 18 (10 Supplement) B41-B41; DOI:10.1158/1078-0432.MECHRES-B41

  • Poster Presentations
    Abstract B42: Heat Shock Protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibition and limits the effectiveness of inhibitors
    Daniele Musiani, Alberto Ramirez Rivera, John David Konda, Simona Pavan, Erica Torchiaro, Martina Olivero and Maria Flavia Di Renzo
    Clin Cancer Res May 15 2012 18 (10 Supplement) B42-B42; DOI:10.1158/1078-0432.MECHRES-B42

  • Poster Presentations
    Abstract B43: Alisertib (MLN8237), an Aurora Kinase A inhibitor, enhances Docetaxel-induced cell death in Upper Gastrointestinal Adenocarcinoma cells
    Vikas Sehdev, Frank Revetta, Abbes Belkhiri, Jeffrey Ecsedy, Alexander Zaika and Wael El-Rifai
    Clin Cancer Res May 15 2012 18 (10 Supplement) B43-B43; DOI:10.1158/1078-0432.MECHRES-B43

  • Poster Presentations
    Abstract B44: Combination treatments of SCLC with ABT-263 and Immunotoxins produces synergistic killing of ABT-263-resistant cells
    Abid R. Mattoo and David J. Fitzgerald
    Clin Cancer Res May 15 2012 18 (10 Supplement) B44-B44; DOI:10.1158/1078-0432.MECHRES-B44

  • Poster Presentations
    Abstract B45: Met-Dependent Positive and Negative Signaling Cascades in Gastric Cancer Cells
    Andrea Z. Lai, Sean Cory, Hong Zhao, Emily S. Bell, Michael Hallett and Morag Park
    Clin Cancer Res May 15 2012 18 (10 Supplement) B45-B45; DOI:10.1158/1078-0432.MECHRES-B45

  • Poster Presentations
    Abstract B46: Targeting tumor-propagating cells in medulloblastoma through inhibition of G2/M cell cycle regulators
    Shirley Markant, Lourdes Adriana Esparza, Kelly Barton, Jesse Sun and Robert Wechsler-Reya
    Clin Cancer Res May 15 2012 18 (10 Supplement) B46-B46; DOI:10.1158/1078-0432.MECHRES-B46

  • Poster Presentations
    Abstract B47: Identification of a novel ALK inhibitor active against Crizotinib-allele resistant mutants
    Jean-Paul Nicolas, Loreley Calvet, Fabrice Vergne, Vincent Leroy, Carlos Garcia-Echeverria, Iris Valtingojer, Laurent Dassencourt, Francoise Herve, Emerson Serres, Laure Delarbre, Meredith Wolfrom, Amanda Lennon, Dietmar Hoffmann and Stephanie Deprets
    Clin Cancer Res May 15 2012 18 (10 Supplement) B47-B47; DOI:10.1158/1078-0432.MECHRES-B47

  • Poster Presentations
    Abstract B48: Sensitization of Hepatocellular Carcinoma Cells to TRAIL by a Novel Aκt/NF-kappaB Signaling Inhibitor
    Hany A. Omar, El-Shaimaa A. Arafa and Jing-Ru Weng
    Clin Cancer Res May 15 2012 18 (10 Supplement) B48-B48; DOI:10.1158/1078-0432.MECHRES-B48

  • Poster Presentations
    Abstract B49: Cancer cell spheroids as a model to study sequential chemotherapy protocols
    Federico Perche and Vladimir P. Torchilin
    Clin Cancer Res May 15 2012 18 (10 Supplement) B49-B49; DOI:10.1158/1078-0432.MECHRES-B49

  • Poster Presentations
    Abstract B50: Per oral nanogel conjugates of activated nucleoside analogs are effective in the treatment of drug-resistant tumors
    Thulani H. Senanayake, Galya Warren, Surender K. Batra, Srikumar M. Raja, Hamid Band and Serguei V. Vinogradov
    Clin Cancer Res May 15 2012 18 (10 Supplement) B50-B50; DOI:10.1158/1078-0432.MECHRES-B50

  • Poster Presentations
    Abstract B52: Design and synthesis of GADD45β agonists for sorefenib-resistance hepatocellular carcinoma cells
    Da-Liang Ou, Hsiang-Hsuan Fan, Chiun Hsu, Ann-Lii Cheng, Cheng-Yi Hsu and Chung-Wai Shiau
    Clin Cancer Res May 15 2012 18 (10 Supplement) B52-B52; DOI:10.1158/1078-0432.MECHRES-B52

  • Poster Presentations
    Abstract B53: Proteasome inhibitor MG132 induces NAG-1 expression through activation of p38 MAPK pathway
    Sachie Shimizu, Harriet Kinyamu, Hiroki Yoshioka, Mitsutoshi Kadowaki, Takashi Watanabe and Thomas Eling
    Clin Cancer Res May 15 2012 18 (10 Supplement) B53-B53; DOI:10.1158/1078-0432.MECHRES-B53

  • Poster Presentations
    Abstract B54: Role of inverted Alu repeats in triggering TMPRSS2-ERG fusions in prostate cancer following irradiation
    Sheetal Singh, Jean P. Cheung, Bay Ho, Andrew Vaughan and Paramita Ghosh
    Clin Cancer Res May 15 2012 18 (10 Supplement) B54-B54; DOI:10.1158/1078-0432.MECHRES-B54

  • Poster Presentations
    Abstract B56: Insights into the role of Epithelial to Mesenchymal transition (EMT) as an important mechanism of drug-resistance to molecular targeted therapies
    Stuart Thomson, Elizabeth Buck, Erica Ullman, Andrew Chau, Peter Mercado, James Bean, Mark Miglarese, David Epstein and John D. Haley
    Clin Cancer Res May 15 2012 18 (10 Supplement) B56-B56; DOI:10.1158/1078-0432.MECHRES-B56

  • Poster Presentations
    Abstract B57: Overcoming Acquired Resistance in Philadelphia-Positive (Ph+) Leukemia
    Mamduh Khateb, Yousef Najajrah, Martin Ruthardt and Jamal Mahajna
    Clin Cancer Res May 15 2012 18 (10 Supplement) B57-B57; DOI:10.1158/1078-0432.MECHRES-B57

  • Poster Presentations
    Abstract B58: The ATP-competitive mammalian target of rapamycin (mTOR) inhibitors suppress proliferation and induce apoptosis in the acquired rapamycin resistant breast cancer cells
    Wu Tzung-Ju, Tsang Chi-Kwan, Zhang Yan-Jie and Zheng X.F. Steven
    Clin Cancer Res May 15 2012 18 (10 Supplement) B58-B58; DOI:10.1158/1078-0432.MECHRES-B58

  • Poster Presentations
    Abstract B59: MET gene copy number related to radiation treatment response and prognosis in breast cancer
    Cynthia Veenstra, Gizeh Pérez-Tenorio, Tommy Fornander, Bo Nordenskjöld and Olle Stål
    Clin Cancer Res May 15 2012 18 (10 Supplement) B59-B59; DOI:10.1158/1078-0432.MECHRES-B59

  • Poster Presentations
    Abstract B60: Overcoming drug resistant cancer by hyaluronic acid based nanogel formulated with anticancer drugs
    Xin Wei, Thulani H. Senanayake and Serguei V. Vinogradov
    Clin Cancer Res May 15 2012 18 (10 Supplement) B60-B60; DOI:10.1158/1078-0432.MECHRES-B60

  • Poster Presentations
    Abstract B61: Picropodophyllin (PPP) increases glucose metabolism and lactate production in paediatric glioblastoma cells
    Anne-Christine Wong Te Fong, Thomas R. Eykyn, Harry G. Parkes, Aleksandra Bielen, Chris Jones, Ian R. Judson, John R. Griffiths, Martin O. Leach and Yuen-Li Chung
    Clin Cancer Res May 15 2012 18 (10 Supplement) B61-B61; DOI:10.1158/1078-0432.MECHRES-B61

  • Poster Presentations
    Abstract B62: Multiple genomic aberrations in BCR-ABL inhibitor-resistant cells lead to sensitivity towards MEK inhibition
    Marie-Claire Wagle, Matthew J. Wongchenko, Vanitha Ramakrishnan, Garret Hampton and Yibing Yan
    Clin Cancer Res May 15 2012 18 (10 Supplement) B62-B62; DOI:10.1158/1078-0432.MECHRES-B62

  • Poster Presentations
    Abstract B63: Heterologous expression of serine palmitoyltransferase-1 alters chemosensitivity and multidrug resistance profile of human cancer cells of different tissue origins
    Tokunbo Yerokun
    Clin Cancer Res May 15 2012 18 (10 Supplement) B63-B63; DOI:10.1158/1078-0432.MECHRES-B63

  • Poster Presentations
    Abstract B64: Development of a novel strategy to overcome drug resistance by targeting ATP citrate lyase and de novo lipogenesis in colorectal cancer cells
    Yunfei Zhou, Federico Tozzi, Ling Xia, Fan Fan, Jia Lu, David Maxwell, Guang Gao, William Bornmann, Zhang Weihua and Lee M Ellis
    Clin Cancer Res May 15 2012 18 (10 Supplement) B64-B64; DOI:10.1158/1078-0432.MECHRES-B64

  • Poster Presentations
    Abstract B65: MicroRNAs in cancer drug resistance and sensitivity
    Jian Zhu
    Clin Cancer Res May 15 2012 18 (10 Supplement) B65-B65; DOI:10.1158/1078-0432.MECHRES-B65

  • Poster Presentations
    Abstract B66: Activation of Wnt/β-catenin signaling enhances TRAIL-dependent apoptosis in human melanoma
    Zachary F. Zimmerman, Andy J. Chien and Randall T. Moon
    Clin Cancer Res May 15 2012 18 (10 Supplement) B66-B66; DOI:10.1158/1078-0432.MECHRES-B66

  • Poster Presentations
    Abstract B67: Increased CXCR4 expression and its nuclear localization are associated with invasion in sorafenib and sunitinib-tolerant hepatocarcinoma models
    Maria Eugenia Riveiro, Armand de Gramont, Eric Raymond, Sandrine Faivre, Maria Serova, Annemilai Tijeras-Raballand, Safi Dokmak, Cindy Neuzillet, Lucile Astorgues-Xerri, Sebastien Albert, Guillemette Huet and Ivan Bieche
    Clin Cancer Res May 15 2012 18 (10 Supplement) B67-B67; DOI:10.1158/1078-0432.MECHRES-B67

  • Poster Presentations
    Abstract B68: Colorectal Cancer in the Setting of Inflammatory Bowel Disease: Role of Hemoglobin
    Michael W. Scaeffer, Amosy E. M'Koma, Joan C. Smith, Billy R. Ballard, Seeley H. Erin, Mary K. Washington, Jeremy L. Norris, Kevin L. Schey, Richard M. Caprioli and Samuel E. Adunyah
    Clin Cancer Res May 15 2012 18 (10 Supplement) B68-B68; DOI:10.1158/1078-0432.MECHRES-B68

Invited Abstracts

  • Invited Abstracts
    Abstract IA1: Keynote Presentation: BRAF and RAS signaling in melanoma from basic to translational and clinical research
    Richard M. Marais
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA1-IA1; DOI:10.1158/1078-0432.MECHRES-IA1

  • Invited Abstracts
    Abstract IA2: Mechanisms of resistance to anti EGFR therapies in colorectal cancers
    Alberto Bardelli
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA2-IA2; DOI:10.1158/1078-0432.MECHRES-IA2

  • Invited Abstracts
    Abstract IA3: PI3K inhibitors in ER+ breast cancer: Next steps
    Matthew J. Ellis, Robert Crowder and Cynthia X. Ma
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA3-IA3; DOI:10.1158/1078-0432.MECHRES-IA3

  • Invited Abstracts
    Abstract IA4: Reciprocal feed-back regulation of the PI3K and AR pathways in prostate cancer: A mechanism of innate resistance
    Brett S. Carver
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA4-IA4; DOI:10.1158/1078-0432.MECHRES-IA4

  • Invited Abstracts
    Abstract IA5: Developing therapeutics in mice with ductal pancreatic cancer
    David A. Tuveson
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA5-IA5; DOI:10.1158/1078-0432.MECHRES-IA5

  • Invited Abstracts
    Abstract IA6: Targeting PI3K in cancer, mechanistic insights from genetic mouse models
    Jean J. Zhao
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA6-IA6; DOI:10.1158/1078-0432.MECHRES-IA6

  • Invited Abstracts
    Abstract IA7: Novel mechanisms of resistance in BRAF-mutant melanoma
    Poulikos I. Poulikakos
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA7-IA7; DOI:10.1158/1078-0432.MECHRES-IA7

  • Invited Abstracts
    Abstract IA8: BRAF and MEK resistance in melanoma
    Meenhard Herlyn and Jessie Villanueva
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA8-IA8; DOI:10.1158/1078-0432.MECHRES-IA8

  • Invited Abstracts
    Abstract IA9: The MEK network as a target for combination therapies
    W. Michael Korn
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA9-IA9; DOI:10.1158/1078-0432.MECHRES-IA9

  • Invited Abstracts
    Abstract IA10: Preemptive or reactive? Drug development strategies in cancers resistant to targeted agents
    Mace L. Rothenberg
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA10-IA10; DOI:10.1158/1078-0432.MECHRES-IA10

  • Invited Abstracts
    Abstract IA11: Using Molecular Profiling Strategies in Clinical Trials to Understand Resistance Mechanisms in the Era of Personalized Cancer Medicine
    Lillian L. Siu
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA11-IA11; DOI:10.1158/1078-0432.MECHRES-IA11

  • Invited Abstracts
    Abstract IA12: Regulatory Considerations in Addressing Resistance Mechanisms
    Ramzi N. Dagher
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA12-IA12; DOI:10.1158/1078-0432.MECHRES-IA12

  • Invited Abstracts
    Abstract IA13: Finding biomarkers of response to targeted cancer drugs through functional genetics
    Rene Bernards
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA13-IA13; DOI:10.1158/1078-0432.MECHRES-IA13

  • Invited Abstracts
    Abstract IA14: Functional genomics to identify cancer targets and resistance
    William C. Hahn
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA14-IA14; DOI:10.1158/1078-0432.MECHRES-IA14

  • Invited Abstracts
    Abstract IA15: VEGF-targeted therapies: Biomarkers, biology, and understanding resistance
    Lee M. Ellis
    Clin Cancer Res May 15 2012 18 (10 Supplement) IA15-IA15; DOI:10.1158/1078-0432.MECHRES-IA15

Proffered Abstracts

  • Proffered Abstracts
    Abstract PR1: NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma
    Tomoya Yamaguchi, Kiyoshi Yanagisawa, Ryoji Sugiyama, Yasuyuki Hosono, Yukako Shimada, Chinatsu Arima, Seiichi Kato, Shuta Tomida, Motoshi Suzuki, Hirotaka Osada and Takashi Takahashi
    Clin Cancer Res May 15 2012 18 (10 Supplement) PR1-PR1; DOI:10.1158/1078-0432.MECHRES-PR1

  • Proffered Abstracts
    Abstract PR2: Stroma-derived matrix metalloproteinase 9 (MMP9) confers resistance to anti-EGFR therapy through cell-extrinsic activation of ERBB2/ERK/JUN pathway
    Janghee Woo, Morikawa Teppei, Shuji Ogino and Ramesh A. Shivdasani
    Clin Cancer Res May 15 2012 18 (10 Supplement) PR2-PR2; DOI:10.1158/1078-0432.MECHRES-PR2

  • Proffered Abstracts
    Abstract PR3: Patient derived BRCA1-deficient triple-negative breast cancer xenografts develop resistance to DNA damaging agents via genetic and epigenetic mechanisms
    Petra ter Brugge, Jelle Wesseling, Jos Jonkers, Eline van der Burg, Petra Kristel, Ute Boon, Cátia Moutinho, Manel Esteller, Frans Hogervorst, Heidrun Gevensleber and Nicholas Turner
    Clin Cancer Res May 15 2012 18 (10 Supplement) PR3-PR3; DOI:10.1158/1078-0432.MECHRES-PR3

  • Proffered Abstracts
    Abstract PR4: Incomplete inhibition of phosphorylation of 4EBP1 is a mechanism for KRAS driven resistance to the ATP-competitive mTOR inhibitor PP242 in colorectal cancer
    Gregory S. Ducker, Chloe E. Atreya, Kevan M. Shokat and Robert S. Warren
    Clin Cancer Res May 15 2012 18 (10 Supplement) PR4-PR4; DOI:10.1158/1078-0432.MECHRES-PR4

  • Proffered Abstracts
    Abstract PR5: Identifying mechanisms of drug resistance to MAPK pathway inhibition via genome-scale rescue screens
    Cory M. Johannessen, Laura A. Johnson, Daniel Lam, Luke Hamm, Federica Piccioni, David Root and Levi Garraway
    Clin Cancer Res May 15 2012 18 (10 Supplement) PR5-PR5; DOI:10.1158/1078-0432.MECHRES-PR5

  • Proffered Abstracts
    Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors
    Timothy R. Wilson, Jane Fridlyand, Antoni Ribas, Jiang Li, Hartmut Koeppen, Mark Merchant, Richard Neve, Jeff Settleman, Yibing Yan, Elicia Penuel, Luciana Burton, Emily Chan, Jing Peng, Eva Lin, Yulei Wang and Jeff Sosman
    Clin Cancer Res May 15 2012 18 (10 Supplement) PR6-PR6; DOI:10.1158/1078-0432.MECHRES-PR6

  • Proffered Abstracts
    Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells
    Seiji Yano, Shinji Takeuchi, Takayuki Nakagawa and Tadaaki Yamada
    Clin Cancer Res May 15 2012 18 (10 Supplement) PR7-PR7; DOI:10.1158/1078-0432.MECHRES-PR7

  • Proffered Abstracts
    Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling
    Ryan B. Corcoran, Kenneth E. Hung, Keith T. Flaherty, Adriano Piris, Jennifer A. Wargo, Jeffrey Settleman, Mari Mino-Kenudson, Jeffrey A. Engelman, Hiromichi Ebi, Alexa B. Turke, Erin M. Coffee, Michiya Nishino, Alexandria P. Cogdill, Ronald D. Brown, Patricia Della Pelle and Dora Dias-Santagata
    Clin Cancer Res May 15 2012 18 (10 Supplement) PR8-PR8; DOI:10.1158/1078-0432.MECHRES-PR8

Back to top
PreviousNext
Clinical Cancer Research: 18 (10 Supplement)
May 2012
Volume 18, Issue 10 Supplement
  • Table of Contents

Sign up for alerts

Jump to

  • Poster Presentations
  • Invited Abstracts
  • Proffered Abstracts
Advertisement
  • Most Cited
  • Most Read
Loading
  • Immune Checkpoint Blockade Requires Macrophage CXCL9/CXCL10
  • PDAC and GATA6 Expression
  • Characterization of Glioblastoma Patient-Derived Xenografts
  • Guadecitabine and Carboplatin in Ovarian Cancer
  • Toxicity Management Affects Checkpoint Inhibitor Efficacy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement